Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up

Journal of Psychopharmacology

Volumn 30, Issue 8, 2016, Pages 795-802

  Kimura, Hiroshi ^a   Kanahara, Nobuhisa ^a   Sasaki, Tsuyoshi ^a,b   Komatsu, Naoya ^b   Ishige, Minoru ^c   Muneoka, Katsumasa ^d   Ino, Hidetoshi ^e   Yoshimura, Kazuyuki ^e   Yamanaka, Hiroshi ^a,f   Suzuki, Tomotaka ^a,g   Komatsu, Hideki ^a,h   Watanabe, Hiroyuki ^a,i   Shimizu, Eiji ^a   Iyo, Masaomi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Dept of Clinical Neurophysiology   (Japan)

^c Sodegaura Satsukidai Hospital   (Japan)

^d Gakuji kai Kimura Hospital   (Japan)

^e Doujin kai Kisaradzu Hospital   (Japan)

^f Chiba Psychiatric Medical Center   (Japan)

^g Department of Psychiatry   (Japan)

^h Choshi Mental Clinic   (Japan)

ⁱ Asahi Central Hospital   (Japan)

Author keywords

Antipsychotic drugs; dopamine; dopamine D2 receptor; dopamine sensitivity; occupancy rate; psychosis; schizophrenia; tardive dyskinesia; tolerance; treatment resistance

Indexed keywords

DOPAMINE; RISPERIDONE; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF PSYCHOTIC RATING SCALE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINE SUPERSENSITIVITY PSYCHOSIS; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; ADOLESCENT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DELAYED RELEASE FORMULATION; INJECTION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; DELAYED-ACTION PREPARATIONS; DOPAMINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84978239430     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881116655978     Document Type: Article

References (29)

1. Chouinard G, (1991) Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment. Schizophr Res 5: 21-33.
2. Chouinard G, Jones BD, (1980) Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry 137: 16-21.
3. Chouinard G, Margolese HC, (2005) Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 76: 247-265.
4. Chouinard G, Jones BD, Annable L, (1978) Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135: 1409-1410.
5. Eerdenkens M, Hove IV, Remmerie B, Mannaert E, (2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70: 91-100.
6. Fallon P, Dursun SM, (2011) A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. J Psychopharmacol 26: 755-762.
7. First MB, Spitzer RI, Gibbon M, et al. (1995) Structured Clinical Interview for DSM-IV Axis I Disorders/Patient Edition (SCID-I/P, version 2.0). New York: New York State Psychiatric Institute.
8. Garfield S, Clifford S, Eliasson L, et al. (2011) Suitability of measures of self-reported medication adherence for routine clinical use: A systematic review. BMC Med Res Methodol 11: 149.
9. Girardi P, Serafini G, Pompili M, et al. (2010) Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 43: 66-72.
10. Gueorguieva R, Krystal JH, (2004) Move over ANOVA: Progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 61: 307-317.
11. Huang N, Ase AR, Hébert C, Van Gelder NM, et al. (1997) Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: Homogenate binding and autoradiographic studies. Neurochem Int 30: 277-290.
12. Inoue A, Miki S, Seto M, et al. (1997) Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 321: 105-111.
13. Iyo M, Tadokoro S, Kanahara N, et al. (2013) Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol 33: 398-404.
14. Juarez-Reyes MG, Shumway M, Battle C, et al. (1995) Eligibility for clozapine among public mental health clients. Psychiatr Serv 46: 801-806.
15. Kapur S, Seeman P, (2001) Does fast dissociation from the dopamine D2 receptor explain the action of antipsychotics? A new hypothesis. Am J Psychiatry 158: 360-369.
16. Kazamatsuri H, Chien CP, Cole JO, (1973) Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 130: 479-483.
17. Kimura H, Kanahara N, Komatus N, et al. (2014) A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 155: 52-58.
18. Kimura H, Kanahara N, Watanabe H, et al. (2013) Potential treatment strategy of risperidone long-acting injectable form for schizophrenia with dopamine supersensitivity psychosis. Schizophr Res 145: 130-131.
19. Kirkpatrick B, Alphs L, Buchanan RW, (1992) The concept of supersensitivity psychosis. J Nerv Ment Dis 180: 265-270.
20. Köhler U, Schröder H, Augusatin W, et al. (1994) A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol-releasing polymers. Neurosci Lett 170: 99-102.
21. Louzã MR, Bassitt DP, (2005) Maintenance treatment of severe tardive dyskinesia with clozapine. 5 years' follow-up. J Clin Psychopharmacol 25: 180-182.
22. Moncrieff J, (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid-onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114: 3-13.
23. Overall JE, Gorham DR, (1962) The brief psychiatric rating scale. Psychol Rep 10: 799-812.
24. Samaha AN, Seeman P, Stewart J, et al. (2007) Breakthrough dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci 27: 2979-2986.
25. Seeman P, Tallerico T, (1999) Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine. Am J Psychiatry 156: 876-884.
26. Silvestri S, Seeman MV, Negrete JC, et al. (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology 152: 174-180.
27. Suzuki T, Kanahara N, Yamanaka H, et al. (2015) Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia. Psychiatr Res 227: 278-282.
28. Takase M, Kanahara N, Oda Y, et al. (2015) Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacology 29: 383-389.
29. Vasconcelos SM, Nascimento VS, Nogueira CR, et al. (2003) Effects of haloperidol on rat behavior and density of dopaminergic D2-like receptors. Behav Processes 63: 45-52.